BCG: Clinical Trials

22 trials of BCG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 22 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Completed 17, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1
Phase 26Completed 5, Terminated 1

Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer
Phase 1RecruitingPfizer2942025-11-062026-11-05
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose - Healthy
Phase 1Active not recruitingStatens Serum Institut1402024-03-142026-03-10
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
BCG Vaccine USP, Isoniazid, Rifampin - Tuberculosis
Phase 1CompletedFred Hutchinson Cancer Center202022-12-062025-12-16
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
BCG for Therapeutic Use - Non-muscular Invasive Bladder Cancer
Phase 1CompletedChengdu CoenBiotech Co., Ltd102022-11-112024-04-05
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
Atezolizumab, BCG - Invasive Bladder Cancer
Phase 1UnknownFundacion Oncosur402020-02-032024-05-21
EMaBS TB Vaccine Study
ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity
Phase 1 / Phase 2CompletedUniversity of Oxford722019-07-012022-08-05
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
Avelumab, BCG - Bladder Cancer
Phase 1 / Phase 2CompletedUniversity of Oklahoma182019-05-012024-02-14
MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa
MTBVAC, BCG - Tuberculosis
Phase 1 / Phase 2CompletedInternational AIDS Vaccine Initiative1442018-05-142023-02-27
Aerosol BCG Challenge Trial in Healthy UK Adults
BCG, Saline placebo - Tuberculosis
Phase 1CompletedUniversity of Oxford462016-03-072023-11-18
Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults
MTBVAC, BCG - Tuberculosis
Phase 1 / Phase 2CompletedBiofabri, S.L542015-09-012018-05-01
Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents
H4:IC31, H56:IC31, BCG - Tuberculosis
Phase 1CompletedAeras842015-05-012019-11-18
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Bacillus Calmette-Guérin (BCG) vaccine, Ipilimumab, Isoniazid - Metastatic Melanoma
Phase 1TerminatedLudwig Institute for Cancer Research52014-03-012022-10-12
Phase I Trial of DAR-901
DAR-901, BCG, Sterile saline - Tuberculosis
Phase 1CompletedDartmouth-Hitchcock Medical Center592014-02-012016-08-02
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
HS-410, Placebo, BCG - Bladder Cancer
Phase 1 / Phase 2TerminatedHeat Biologics1042013-12-012020-02-17
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
Mitomycin C - Urinary Bladder Neoplasm
Phase 1CompletedThe University of Texas Health Science Center at San Antonio182012-03-012015-12-03
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
MAGE-A3 ASCI, BCG - Bladder Cancer
Phase 1CompletedPatrice Jichlinski232012-01-012015-02-04
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers
VPM1002, BCG - Tuberculosis, Healthy
Phase 1CompletedSerum Life Science Europe GmbH802008-09-012010-05-20
Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics
BCG, Saline - Type 1 Diabetes Mellitus
Phase 1CompletedMassachusetts General Hospital252007-11-012013-11-05
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
BCG - Tuberculosis
Phase 1CompletedUniversity of Oxford402007-08-012010-07-01
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
BCG - TB
Phase 1CompletedUniversity of Oxford112004-02-012008-04-07

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Tuberculosis (11)  ·  Urinary Bladder Neoplasms (8)  ·  Non-Muscle Invasive Bladder Neoplasms (2)  ·  Autoimmune Diseases (1)  ·  Diabetes Mellitus, Type 1 (1)  ·  Melanoma (1)  ·  Neoplasms (1)

Sponsors

University of Oxford (5)  ·  Aeras (1)  ·  Biofabri, S.L (1)  ·  Chengdu CoenBiotech Co., Ltd (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Fundacion Oncosur (1)  ·  Heat Biologics (1)  ·  International AIDS Vaccine Initiative (1)  ·  Ludwig Institute for Cancer Research (1)  ·  Massachusetts General Hospital (1)  ·  Patrice Jichlinski (1)  ·  Pfizer (1)  ·  Serum Life Science Europe GmbH (1)  ·  Statens Serum Institut (1)

Countries

United States (7)  ·  United Kingdom (6)  ·  South Africa (4)  ·  Spain (2)  ·  Australia (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  Uganda (1)

Top investigators

Helen McShane (2)  ·  Angelique Luabeya, MD (1)  ·  Charles F. von Reyn, MD (1)  ·  Daniel Castellano, MD (1)  ·  David M Nathan, MD (1)  ·  Gary Steinberg, MD (1)  ·  Gavin Churchyard, PhD (1)  ·  Helen I McShane (1)  ·  Helen McShane, Professor (1)  ·  James Kublin, MD, MPH (1)  ·  Jim Kublin, MD (1)  ·  Jonathan Cebon, MD, PhD (1)  ·  Kelly Stratton, MD (1)  ·  Linda-Gail Bekker, MD (1)

Results publications

PMID 15502839, PMID 19529780, PMID 22905105, PMID 23290835, PMID 28498853, PMID 29552014, PMID 29685114, PMID 29915522, PMID 31120957, PMID 31416768, PMID 32382714, PMID 38621405, PMID 42008114, PMID 42648772

NIH funding

2019 (1)